Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Feb 26 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced the receipt of WHO prequalification for Miltefosine, a key drug for treating Leishmaniasis, also known as Kala Azhar. This approval will facilitate greater global access to the drug, which is crucial for treating a disease that affects some of the world's poorest populations. The press release highlights the significance of this milestone in combating Leishmaniasis, which has severe health implications if left untreated.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases